News
Important Only
Gold holds steady as markets eye US-China trade talks
US-China trade talks set to extend to a second dayTrump says 'doing well' with ChinaBy Anmol Choubey June 10 (Reuters) - Gold prices were steady on Tuesday as market participants awaited developments from the second day of U.S.-China trade talks in London, while a stronger dollar limited ...Reuters
Tue, Jun 10
Ericsson and Supermicro Advance Enterprise Connectivity for Edge AI Systems
Ericsson and Supermicro explore cooperation on innovative 5G bundle for rapid time-to-deployment for multiple AI edge applications SAN JOSE, Calif. and PARIS, June 10, 2025 /PRNewswire/ -- Ericsson (NASDAQ: ERIC) and Supermicro (NASDAQ: SMCI) -- today announced an intent to engage in a strategic c...PR Newswire
Tue, Jun 10
LIVE MARKETS-Before the bell: futures point to steady start
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com BEFORE THE BELL: FUTURES POINT TO STEADY STARTEuropean shares were set to open broadly unchanged on Tuesday as investors awai...Reuters
Tue, Jun 10
UK Stocks-UK Factors to watch on June 10
June 10 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.2%.* BELLWAY: British homebuilder Bellway BWY.L raised its full-year volume output forecast on Tuesday to 8,600–8,700 homes from 8,500 homes, supported by stronger spring sales and impro...Reuters
Tue, Jun 10
MegaPro Unveils Promising Phase I Results for Tween-80-Free Anti-Cancer Drug MPB-1734
Taipei, June 10, 2025 — MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro” , TWSE: 6827), a clinical-stage biopharmaceutical company, today announced strong Phase I clinical results for its next-generation anti-cancer drug, MPB-1734. Developed using MegaPro’s proprietary nano-micelle platform, MPB-1734 is a novel, Tween-80-free formulation of cabazitaxel (Jevtana®), designed to reduce toxicity and enhance clinical outcomes in patients with advanced solid tumors.Key findings reveal that MPB-1734 offers a safer, more tolerable treatment profile—with fewer blood-related and gastrointestinal side effects—while maintaining potent anti-tumor activity. Based on these outcomes, the recommended Phase II dose has been set at 25 mg/m², higher than the currently approved dose for cabazitaxel (20 mg/m²), highlighting the potential for superior efficacy with fewer trade-offs.Key Highlights from the Phase I Trial:No Allergic ReactionsUnlike traditional cabazitaxel, which carries a black box warning for hypersensitivity due to its use of Tween-80, MPB-1734 showed no allergic responses in any patients.Improved Safety ProfileAt 25 mg/m², MPB-1734 demonstrated a Grade ≥3 neutropenia rate of just 29%, a sharp reduction compared to >80% with cabazitaxel. No moderate or severe diarrhea was observed, compared to 6% Grade 3 incidence with the reference drug.Encouraging Early EfficacyIn evaluable patients, disease control was achieved in 76.9%, with a clinical benefit rate of 61.5%. One patient with head and neck cancer achieved a partial response lasting over 30 treatment cycles, and seven patients maintained stable disease.No Peripheral Neuropathy ObservedUnlike conventional taxane-based drugs, which frequently cause nerve damage (7–13% incidence in CBZ), no cases of peripheral neuropathy were reported in any MPB-1734 patients.President Commentary“This data represents a breakthrough in formulation science,” said Dr. Yuan-Hung Hsu, Presiden of MegaPro. “By removing Tween-80, we not only reduced adverse events but also preserved—and possibly enhanced—therapeutic impact. MPB-1734 is a strong candidate for patients needing better tolerated second-line therapies, especially in hard-to-treat tumors.” Dr. Hsu added, “Our results in non-approved indications like head and neck cancer are especially exciting. MPB-1734 has the potential to expand cabazitaxel’s therapeutic reach while improving patients’ quality of life.”What’s NextMegaPro has completed its Phase I data analysis and is preparing to initiate the next stage of development after its upcoming fundraising round. The company plans to pursue accelerated regulatory approval via the 505(b)(2) pathway, enabling a faster path to market. This milestone positions MegaPro to unlock significant value in the oncology treatment landscape and drive the next phase of company growth.10/06/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Tue, Jun 10
MegaPro Unveils Promising Phase I Results for Tween-80-Free Anti-Cancer Drug MPB-1734
Taipei, June 10, 2025 — MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro” , TWSE: 6827), a clinical-stage biopharmaceutical company, today announced strong Phase I clinical results for its next-generation anti-cancer drug, MPB-1734. Developed using MegaPro’s proprietary nano-micelle platform, MPB-1734 is a novel, Tween-80-free formulation of cabazitaxel (Jevtana®), designed to reduce toxicity and enhance clinical outcomes in patients with advanced solid tumors.Key findings reveal that MPB-1734 offers a safer, more tolerable treatment profile—with fewer blood-related and gastrointestinal side effects—while maintaining potent anti-tumor activity. Based on these outcomes, the recommended Phase II dose has been set at 25 mg/m², higher than the currently approved dose for cabazitaxel (20 mg/m²), highlighting the potential for superior efficacy with fewer trade-offs.Key Highlights from the Phase I Trial:No Allergic ReactionsUnlike traditional cabazitaxel, which carries a black box warning for hypersensitivity due to its use of Tween-80, MPB-1734 showed no allergic responses in any patients.Improved Safety ProfileAt 25 mg/m², MPB-1734 demonstrated a Grade ≥3 neutropenia rate of just 29%, a sharp reduction compared to >80% with cabazitaxel. No moderate or severe diarrhea was observed, compared to 6% Grade 3 incidence with the reference drug.Encouraging Early EfficacyIn evaluable patients, disease control was achieved in 76.9%, with a clinical benefit rate of 61.5%. One patient with head and neck cancer achieved a partial response lasting over 30 treatment cycles, and seven patients maintained stable disease.No Peripheral Neuropathy ObservedUnlike conventional taxane-based drugs, which frequently cause nerve damage (7–13% incidence in CBZ), no cases of peripheral neuropathy were reported in any MPB-1734 patients.President Commentary“This data represents a breakthrough in formulation science,” said Dr. Yuan-Hung Hsu, Presiden of MegaPro. “By removing Tween-80, we not only reduced adverse events but also preserved—and possibly enhanced—therapeutic impact. MPB-1734 is a strong candidate for patients needing better tolerated second-line therapies, especially in hard-to-treat tumors.” Dr. Hsu added, “Our results in non-approved indications like head and neck cancer are especially exciting. MPB-1734 has the potential to expand cabazitaxel’s therapeutic reach while improving patients’ quality of life.”What’s NextMegaPro has completed its Phase I data analysis and is preparing to initiate the next stage of development after its upcoming fundraising round. The company plans to pursue accelerated regulatory approval via the 505(b)(2) pathway, enabling a faster path to market. This milestone positions MegaPro to unlock significant value in the oncology treatment landscape and drive the next phase of company growth.10/06/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Tue, Jun 10
Pop Mart Hits New Heights: Labubu Dominates the Global Toy Trend!
TradingKey - Recently, Pop Mart (09992.HK) has shown outstanding performance in both the capital market and the toy market. On Tuesday, its stock price briefly touched HKD 262, setting a new historical record. Since the beginning of this year, Pop Mart's stock has risen by over 180%, and since FebruTradingKey
Tue, Jun 10
GLOBAL MARKETS-Stocks, dollar climb as investors hope for US-China trade talk progress
Investors await details from U.S.-China talks, hope for reliefMSCI's Asia stocks index touches three-year high Dollar limps ahead versus peersJGB bond yields slip from record highsBy Rae Wee and Johann M Cherian SINGAPORE, June 10 (Reuters) - Global stocks rose and the dollar edged higher...Reuters
Tue, Jun 10
Huawei chips are one generation behind US but firm finding workarounds, CEO says
BEIJING, June 10 (Reuters) - Huawei Technologies' HWT.UL chips are one generation behind those of U.S. peers but the firm is finding ways to improve performance through methods such as cluster computing, Chinese state media quoted CEO Ren Zhengfei as saying on Tuesday.Reuters
Tue, Jun 10
LIVE MARKETS-Investors itching for progress in US-China talks
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.comINVESTORS ITCHING FOR PROGRESS IN US-CHINA TALKS A look at the day ahead in European and global markets from Johann M CherianWit...Reuters
Tue, Jun 10
Asian stocks climb, FX steady as US-China trade talks set to continue
June 10 (Reuters) - Stock markets in Asia climbed on Tuesday and regional currencies were little changed against a steady U.S. dollar, as investors monitored the second day of trade negotiations between the United States and China.Reuters
Tue, Jun 10
EMERGING MARKETS-Asian stocks climb, FX steady as US-China trade talks set to continue
MSCI Asia ex-Japan index hits highest level since January 2022Taiwan stocks jump over 2% to a two-week highUS-China talks to continue on TuesdayBy Roshan Thomas June 10 (Reuters) - Stock markets in Asia climbed on Tuesday and regional currencies were little changed against a steady U.S. dollar, a...Reuters
Tue, Jun 10
UK Stocks-UK Factors to watch on June 10
June 10 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.16%.* THAMES WATER: Thames Water's bondholders have offered to inject 5 billion pounds ($6.8 billion) in new equity and debt and write off some existing borrowing to rescue the utili...Reuters
Tue, Jun 10
MORNING BID EUROPE-Investors itching for progress in US-China talks
A look at the day ahead in European and global markets from Johann M CherianWith precious little to report out of Sino-U.S. trade talks in London, investors are ready to pounce on almost any sign a thaw in the frigid relationship between the two superpowers is just around the corner.Stocks in Asia a...Reuters
Tue, Jun 10
Australia's FirstWave Cloud Technology hits over 2-week high on deal with Amazon's unit
** Shares of FirstWave Cloud Technology FCT.AX rise 23.1% to A$0.016, their highest since May 26** The tech firm secures partnership with Amazon Web Services, a unit of Amazon AMZN.O and private U.S. company Corent Technology** Deal to further develop and deploy the company's product suite on th...Reuters
Tue, Jun 10
China-U.S. London Talks Signal Strongest Concessions Yet, Chip Stocks Surge! Hassett Says "Any" Export Controls to Be Eased
TradingKey - During the first day of the first meeting of the China-U.S. economic and trade consultation mechanism in London, the U.S. conveyed positive progress and a willingness to make broad concessions. News of potential eased semiconductor export restrictions to China boosted the semiconductor
TradingKey
Tue, Jun 10
Australia's Firstwave Cloud Technology soars on partnership with Amazon Web Services
** Shares of Firstwave Cloud Technology FCT.AX rise 23.1% to A$0.016, set for their best day since April 10** Tech co's stock rose as much as 38.5% earlier in the session to hit its highest since May 19** Co enters strategic partnership with Amazon Web Services and U.S.-based Corent Technology**...Reuters
Tue, Jun 10
GLOBAL MARKETS-Stocks rise, dollar tentative ahead of US-China talks outcome
Investors hold nerve ahead of details from U.S.-China talksStocks gain, dollar pares some lossesJGB yields fall from record highsBy Rae Wee and Johann M Cherian SINGAPORE, June 10 (Reuters) - Stocks were buoyant and the dollar remained on guard on Tuesday as trade talks between the United States ...Reuters
Tue, Jun 10
Australia's Argenica Therapeutics tumbles as FDA halts stroke drug application
** Biotech firm Argenica Therapeutics shares AGN.AX fall 10.8% to A$0.7, lowest level since May 1** Stock poised for weakest session since early April, if trends sustain** U.S. FDA holds co's Investigational New Drug Application, finding its data "inadequate" for clinical trials of acute...Reuters
Tue, Jun 10
